Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
1999-10-20
2003-12-30
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S027000, C514S182000, C514S183000, C514S450000, C514S026000, C536S006400, C552S502000, C552S625000, C552S638000, C540S002000, C540S107000, C540S109000, C540S112000, C540S113000, C540S115000, C540S461000, C549S268000
Reexamination Certificate
active
06670348
ABSTRACT:
FIELD OF THE INVENTION
This application relates to the use of ansamycin antibiotics as targeted therapeutic agents for the destruction of selected proteins and to novel compositions suited for this use. Destruction of selected proteins in accordance with the invention can be used in the treatment of cancer.
BACKGROUND OF THE INVENTION
Targeted delivery of therapeutic agents as a means for treating cancer has been proposed by many authors. Conceptually, the idea is to deliver a toxic substance selectively to the cancer cells, thus reducing the general toxicity to the patient. This is theoretically possible, since many cancer cell types have been found to have increased levels of hormone receptors and similar receptors. For example, breast cancer cells may have elevated levels of HER2 receptors or estrogen receptors which result in hormone-stimulated growth of cancer cells, while androgen receptors are required for growth of many prostate cancers and mutation of the androgen receptors frequently occurs in advanced prostate cancer.
Hormone receptors have been used in studies on the feasibility of using direct targeted chemotherapy agents to certain classes of cells. Thus, for example, Lam et al.,
Cancer Treatment Reports
71: 901-906 (1987) have reported on estrogen-nitrosourea conjugates as potential cytotoxic agents against human breast cancer, while Brix et al.,
J. Cancer Res.
116: 538-539 (1990) have reported on studies of the use of androgen-linked alkylating agents as antineoplastic agents. See also, Eisenbrand et al.,
Acta Oncologica
28: 203-211 (1989). Myers and Villemez,
Biochem. Biophys. Res. Commun.
163: 161-164 (1989) have disclosed the possibility of utilizing luteinizing hormone coupled to a truncated diphtheria toxin.
Benzoquinoid ansamycin antibiotics such as geldanamycin and herbimycin A are known to induce the destruction of certain protein tyrosine kinases including HER-2 receptors, insulin and insulin-like growth factor receptors and members of the src-family and
raf
kinase. In addition, benzoquinoid antibiotics can induce the selective degradation in vivo of receptors, including estrogen, androgen and progesterone receptors.
SUMMARY OF THE INVENTION
We have now found that compounds having an ansamycin antibiotic coupled to a targeting moiety which binds specifically to a protein, receptor or marker can provide effective targeted delivery of the ansamycin antibiotic leading to the degradation of proteins and death of the targeted cells. These compositions may have different specificity than the ansamycin alone, allowing for a more specific targeting of the therapy, and can be effective in instances where the ansamycin alone has no effect. Thus, the present invention provides an entirely new class of targeted chemotherapy agents with application, depending on the nature of the targeting moiety, to treatment of a variety of different forms of cancer. Such agents can further be used to promote selective degradation of proteins associated with the pathogenesis of others diseases, including antigens associated with autoimmune disorders and pathogenic proteins associated with Alzheimer's disease.
Compounds in accordance with the invention comprise a targeting moiety which specifically binds to a target protein or cell population, and an ansamycin antibiotic, preferably separated by a spacer. Exemplary targeting moieties which may be employed in compounds of the invention include testosterone, estradiol, and tamoxifen. Preferred ansamycin antibiotics are geldanamycin and herbimycin A.
REFERENCES:
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 5650430 (1997-07-01), Sugimura et al.
patent: 5932566 (1999-08-01), Schnur et al.
patent: 5968921 (1999-10-01), Gold
patent: 6239168 (2001-05-01), Ino et al.
Bohen, S.P. “Genetic and Biochemical analysis of p23 and Ansamycin Antibiotics in the Function of HSP90-Dependent Signaling Proteins”, Molecular and Cellular Biology, Jun. 1998, vol. 18, No. 6, pp 3330-3339.
Pratt, W.B. “The hsp90-based Chaperone System: Involvement in Signal Transduction from a Variety of Hormone and Growth Factor Receptors”, Proceedings of the Society for Experimental Biology and Medicine, Apr. 1998, vol. 217, No. 4, pp 420-434, especially p. 421.
Scheibel, et al, “Two Chapperone Sites in Hsp90 Differing in Substrate specificity and ATP Dependence”, Proceedings of the National Academy of Sciences of the USA, Feb. 17, 1998, vol. 95, No. 4, pp 1495-1499, especially p. 1495.
Chen, et al, “The Ah Receptor Is a Sensitive Target of Geldanamycin-Induced Protein Turnover”, Archives of Biochemistry and Biophysics, Dec. 1, 1997, vol. 348, No. 1, pp 190-198, especially p. 190.
Landel, et al, “Estrogen Receptor Accessory Proteins Augment Receptor-DNA Interaction and DNA Bending”, The Journal of Steroid Biochemistry & Molecular Biology, vol. 63, No. 1-3, pp 59-73, especially pp. 59-61, 1997.
Bamberger, et al, “Inhibition of Mineralocorticoid and Glucocorticoid Receptor Function by the Heat Shock Protein 90-Binding Agent Geldanamycin”, Molecular and Cellular Endocrinology, Aug. 8, 1997, vol. 131, No. 2, pp 233-240, especially pp 237-239.
Segnitz, et al, “The Function of Steroid Hormone Receptors Is Inhibited by the hsp90-specific Compound Geldanamycin”, The Journal of Biological Chemistry, Jul. 25, 1997, vol. 272, No. 30, pp 18694-18694.
Munster et al., “Inhibition of Heat Shock Protein 90 Function by Ansamycins Causes the Morphological and Functional Differentiation of Breast Cancer Cells”,Cancer Research. Apr. 1, 2001, vol. 61, pp 2945-2952.
Schulte et al., “The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin”,Cancer Chemotherapy and Pharmacology, 1998, vol. 42, pp 273-279.
Hurst, S. et al., “HSP90 inhibitors block the mitotic checkpoint and are synergistically toxic with spindle poisons”,Clinical Cancer Res., Nov. 1999, vol. 8, p. 3788s, #293.
Kherfellah, d. et al, “Effect of the combination of topoisomerase I and topoisomerase II inhibitors on rat glioblastoma cells and drug-resistant variants”,Pharmacol. Experimental Therapeutics, Mar. 1999, vol. 40, p. 109, #724.
Stebbins, c. E. et al, “Crystal structure of the Hsp90-Geldanamycin complex: targeting of a protein chaperone by an antitumor agent”,Cell, Apr. 1997, vol. 89, pp. 239-240 and 246-248.
Rosenhagen, M. C. et al, “Synergistic inhibition of the Glucocorticoid receptor by radicicol and benzoquinone ansamycins”,Biol. Chem., Mar. 2001, vol. 382, pp. 499-504.
Chavany, et al. “p185erbB2Binds to GRP94 in Vivo”, Journal of Biological Chemistry, vol. 271, No. 9 Mar. 1, 1996, pps. 4974-4977.
Neckers, “Effects of Geldanamycin and Other Naturally Occurring Small Molecule Antagonists of Heat Shock Protein 90 on HER2 Protein Expression”, Breast Disease 11 (2000) 49-59. pps. 49-59.
Schnur, et al. “erbB-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure—Activity Relationships”, J. Med. Chem. 1995, 38, 3813-3820.
Danishefsky Samuel
Kuduk Scott D.
Ouerfelli Ouathek
Rosen Neal
Sepp-Lorenzino Laura
Raymond Richard L.
Sloan-Kettering Institute for Cancer Research
LandOfFree
Methods and compositions for destruction of selected proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for destruction of selected proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for destruction of selected proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3115831